Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 1998

View Archived Issues

Laminin-related polypeptides from the University of Minnesota

Matritech receives SBIR grant for cancer test development

SS Pharm. describes new triazoles with oral activity

Squalene synthase inhibitors patented by Pfizer

Imidazoles for reversing MDR prepared at Ontogen

Dual 5-HT reuptake inhibitors/5-HT1A antagonists developed at Lilly

Virus-host cell fusion inhibitors under study at Lilly

Agents for schizophrenia without EPS disclosed by Warner-Lambert

New heterocyclic bradykinin antagonists from Fujisawa

Ortho reveals new fibrinogen receptor antagonists

Two NDAs up for review this week by Cardiovascular and Renal Drugs Advisory Committee

Neuroprotective effects of new PARS inhibitor

European alliance formed by Faulding and Asta Medica

Theratechnologies' novel cancer treatment granted additional patent protection

ProstaScint may predict response of prostate cancer patients to salvage radiotherapy

Clinical trial status of pain control implant updated by CytoTherapeutics/Astra

Expansion of Advanced Tissues Sciences/Smith & Nephew joint venture planned

Pfizer updates development pipeline

Nabi's Altastaph enters phase I/II

Additional data submitted to FDA to support Novastan NDA

Atherosclerosis program at Genome Therapeutics expanded

Adenosine metabolism inhibitor research at Cypros supported by grant

Randomized trial compares interferon alfa-2b + ribavirin to interferon alone for HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...